Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report

Affiliations

• ¹ Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221006, Jiangsu, China.
• ² Cancer Institute, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
• ³ Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
• ⁴ Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221006, Jiangsu, China.
• ⁵ Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221006, Jiangsu, China.
• ⁶ Neuroimmunology Group, KingMed Diagnostic Laboratory, Guangzhou, China.
• ⁷ Cancer Institute, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China. mingshi@xzhmu.edu.cn.
• ⁸ Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China. mingshi@xzhmu.edu.cn.
• ⁹ Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221006, Jiangsu, China. mingshi@xzhmu.edu.cn.
• ¹⁰ Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221006, Jiangsu, China. jnzheng@xzhmu.edu.cn.
• ¹¹ Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221006, Jiangsu, China. cuiguiyun1017@126.com.